[Skip to Navigation]
Editor's Note
November 17, 2021

Race Bias in Transcatheter Aortic Valve Replacement: Are We Sure?

Author Affiliations
  • 1Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 2Deputy Editor, JAMA Cardiology
  • 3Columbia University Irving Medical Center/NewYork–Presbyterian Hospital, New York
  • 4Associate Editor, JAMA Cardiology
JAMA Cardiol. 2022;7(2):158. doi:10.1001/jamacardio.2021.4647

Despite breakthrough science and innovative procedures, cardiovascular disease is rife with evidence-based racial disparities. Adopting quality initiatives, raising awareness, and inciting discussions about unconscious bias are recommended steps intended to narrow cardiovascular disease disparities. Progress is noted but a new challenge emerges. The implementation of transcatheter aortic valve replacement (TAVR), a life-sustaining technology, appears to mirror past patterns of race-based disparities. Has there been no real progress?

Add or change institution